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Abstract
Background: The hypercoagulability of  pregnancy is exaggerated in pre-eclamptic state because  of   endothelial  activation 
with  resultant  production  of   some  endothelial  derived proteins that are said to be inhibitors of  fibrinolysis. This study com-
pares these proteins like tPA, PAI-1 and D-dimers in normal pregnant women and the pre-eclamptic women.
Methodology: This was a comparative cross-sectional study. Eighty-five pre-eclamptic women were recruited as subjects and 
eighty five age, trimester and parity matched normotensive pregnant  women  as  controls.  Levels  of   PT,  aPTT,  tPA,  PAI-1, 
D-dimer  protein    were determined in blood samples of  subjects and controls. Urinalysis was performed with dipstick method 
on  their  urine  samples.  Data  generated  was  analysed  using  the IBM®SPSS  20.0 (2011) soft ware packages and the level 
of  significance was a p-value <0.05.
Results:  The mean age of  the respondents  was 29.9±5.2 years. The  median(25th-75th percentile)  values  of   D-dimer,   tPA, 
and PAI-1  of   subjects  were  730  (305.000-1560.000ng/ml),   0.11 (0.065-0,300ng/ml) and 3.65 (2.970-4,400ng/ml) respec-
tively which were significantly higher than the corresponding   values  in  the  controls  of   520  (24.000-1030.000ng/ml),   0.05 
(0.040-0.090ng/ml  and  2.650 (2.125-3.400ng/ml) respectively, p<0.05 each.
Conclusion: The abnormal levels of  PAI-1,D-dimer and tPA imply that they contribute to the exaggerated hypercoagulabilty 
state in pre-eclampsia thus, measuring their levels can help in the management of  the condition.
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Introduction 
Normal haemostasis is a complex network of  interac-
tions with positive and negative feedback loops which in-
tegrate at least five major components namely the blood 
vessels, the platelets both in number and functions, the 
coagulation factors and their co-factors, coagulation fac-
tor inhibitors and the fibrinolytic pathway.1
 
Activation of  the coagulation factors, the blood vessels 
and platelets results in the formation of   a  firm,  defin-
itive  and  stable  haemostatic  plug  while  the  removal 
of   the product  of  coagulation,  namely fibrin from the 
circulation is the function of  the fibrinolytic system. This 
makes fibrinolysis a normal response to vascular injury 
similar to coagulation.1
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Pregnancy, a physiological condition however is associ-
ated with a profound change in both coagulation as well 
as the fibrinolytic systems.2,3  These changes are such 
that coagulation is enhanced by the virtue of  increased 
synthesis of  all the coagulation factors most especially fi-
brinogen, factors VIII, IX, X and a significant reduction 
in the fibrinolytic pathway due to increased synthesis of  
plasminogen activator inhibitors type 1 and 2, all these 
making pregnancy a hypercoagulable state.
 
The purpose of  these changes is to minimize bleeding 
during and after placental separation at parturition.4   The 
changes in the coagulation and fibrinolytic system is even 
more pronounced in pregnancy induced hypertension 
and in eclampsia.
 
Pre-eclamptic  toxaemia  (PET)  is  a  disease  of   preg-
nancy  occurring  after  twenty  weeks gestation, and char-
acterized by blood pressure of  140/90mmHg or above-
on two occasions about 4-6 hours apart with a preceding 
normal blood pressure. The increase in blood pressure 
is  associated  with  significant  proteinuria  (300mg  in 
24 hours). These  features  all  resolve completely by the 
sixth postpartum week.5  Pre-eclampsia is a pregnan-
cy-specific syndrome of  decreased organ perfusion due 
to vasospasm and endothelial activation.6
 
Roberts and colleagues  proposed that alterations in endo-
thelial  cell function by activating agents, produced by the 
placenta, initiates the clinical syndromes of  pre-eclamp-
sia.7  Also, unknown  factor(s),  likely from the placenta 
are secreted into the maternal circulation  and provoke 
activation and dysfunction of  the vascular endothelium.8 
Therefore, endothelial cell injury or activation is believed 
to play a central  role in pre-eclampsia and may underlie 
the haemostatic changes observed in this syndrome.9 Fac-
tors like,  tPA,  fibronectin, PAI-1 are endothelial derived 
and may be markers of  endothelial activation in pre-ec-
lampsia.10,11
 
The  localized  elevated  concentration  of  placental  PAI-
1  and PAI-2   protein and  mRNA observed in PET pa-
tient would be expected to foster the deposition of  fibrin 
and thus play a role  in  the  complications  associated 
with  the  disease  for  example,  fibrin  deposition  in 
placental and other organs causing infarction.12
 
Therefore pre-eclampsia is characterized by a maternal 
hypercoagulable state,intravascular coagulation,   micro-
thrombosis   in  several  organs  and  impairment   of  
the  uteroplacental circulation. Also, the evidence of  this 
was suggested by Tanjung,who described PET as a state 
of  enhanced thrombin generation with alteration in the 
coagulation pathway.13,14
 
Based upon this background, this study determined and 
compared the PCV, platelet count, Prothrombin time 
(PT), activated partial thromboplastin time (aPTT), tPA, 
PAI-1,D-dimer, of  pre-eclamptic subjects and normoten-
sive non-proteinuric pregnant women and to find out if  
there would be significant differences in their values.
Methodology
The study was carried out at the Obstetrics emergency 
ward and antenatal clinic of  Obstetrics & Gynaecology 
department, and the department of  Haematology and 
Blood transfusion, all of  the University of  Ilorin Teach-
ing Hospital (UITH), Ilorin between November 2012 and 
February 2013, about three months..
 
It was a comparative cross-sectional non-intervention 
based study that included 85 subjects with pre-eclampsia 
aged 18-42 years who were yet to be delivered of  their-
pregnancies. Also, age,  parity  and  trimester  matched 
normotensive  non-proteinuric pregnant  women  were 
recruited as controls. Sample size was calculated using 
the formular that compares Two Group Means15; n=1 + 
2c(s/d)2 , where  n= minimal sample size, c= 10.5(a con-
stant) if  α= 0.05 and 1-β=0.9, s= Standard deviation(SD) 
of  D-dimer in pre-eclampsia from the literature,  d= dif-
ference in SD of  D-dimer in pre-eclamptic and SD of  
D-dimer in normotensive pregnant women, where SD of  
D-dimer in pre-eclampsia from the literature16 = 1.07µg/
ml and SD of  D-dimer in normotensive pregnant wom-
en16 = 0.51 µg/ml and d=1.07- 0.51=0.56 µg/ml. There-
fore, the calculated sample size was 77. After correcting 
for an anticipated attrition rate of  10%, the sample size 
was 85.
 
Pre-eclampsia  was  diagnosed  according  to  the  criteria 
of   the  National  Blood  Pressure Education Program 
Working Group as blood pressure of  140/90mmHg 
and confirmed proteinuria (0.3g/L/24h)  with or with-
out   previous evidence of  an underlying hypertensive 
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disorder.17  Confirmed pregnant women beyond 20 weeks 
gestation who were normotensive and had no proteinuria 
were recruited as controls.
 
However, pregnant women with arterial or venous throm-
bosis, post-operative  and trauma cases, pregnant women 
with significant  medical disorders such as, diabetes melli-
tus,chronic renal failure, or on any form of  anticoagulant 
therapy and those  who declined consent were excluded 
from the study.
 
Ethical clearance was obtained from the Ethics and Re-
search Committee of  the University of  Ilorin Teaching 
Hospital. Written informed consent was obtained from 
the patients after explaining the aim of  the study and the 
procedure involved. A study pro-forma was used to ob-
tain information on socio-demographic parameters and 
obstetric history.
 
Eight and half  millilitres (ml) of  venous blood was tak-
en by standard sterile procedure from each subjects in-
cluded in this  study. Four and half  ml out of  the whole 
blood  was put  plastic tubes containing half  ml sodium 
citrate(3.8%), and four ml was dispensed into a bottle 
containing  ethylene  diamine  tetra  acetic acid(EDTA). 
Both  bottles  were  gently  mixed  to allow proper mix-
ture of  the blood sample with the anticoagulant.
The sample in the citrate bottle was centrifuged for 20 
mins at 3500g to obtain a platelet-poor supernatant,  and 
the  supernatant  plasma  stored  at -800C  until  assayed. 
The  blood  in  the EDTA bottle was used for the esti-
mation of  packed cell volume (PCV), platelet count with-
in two hours of  collection. The same method of  blood 
collection and storage was done for the controls.  Also, 
a  urine  sample  from  each  patient  and  contol  subject 
was  obtained  in  a universal plain bottle and analyzed-
immediately by urinalysis.
 
The following tests were carried out on the blood sample: 
PCV, Platelet count,Prothrombin time, Activated partial 
thromboplastin time (aPTT), D-dimer assay,Tissue plas-
minogen activator, Plasminogen activator inhibitor-type 
1.
 
The platelet count and PCV was performed on all sam-
ples using the sysmex KX21® (Sysmex Corporation, 
Kobe, Japan) automated cell counter.
 
Prothrombin Time was determined using commercially 
prepared reagents based on the one stage test of  Owren.
 
Activated  Partial  Thromboplastin   Time  was  deter-
mined  using commercially   prepared reagents based on 
the method of  Proctor and Rapaport.   Tissue plasmin-
ogen activator was assay using a AssayMax Human tPA 
ELISA kit(Product of  Saint Charles, Missouri, USA). 
Plasminogen  activator  inhibitor  type-1  (PAI-1)  was 
determined  using  AssayMax Human PAI-1  ELISA  kit 
(Product  of   Saint Charles,  Missouri,  USA).  Assess-
ment  of   D-DIMER ASSAY was by TECHNOZYM 
D-dimer ELISA kit (Product of  Technozyme, Austria) .
Data analysis was done using the IBM® SPSS version 
20.0 (IBM corporation,Virgina, USA) 2011 for windows 
software  package.  After the generation  of  frequency 
tables and simple proportions,  Student’s  t-tests and 
Mann-Whitney  U tests were used to identify significant 
differences for normally distributed continuous variable 
and the skewed data respectively. Fisher’s exact test were 
used for testing the significance of  associations from cells 
with small numbers (<5) as appropriate.
 
Results
The mean age of  respondents was 29.9±5.2, majority 
72(84.7%) were 19-35years and only 2(2.4%) were aged 
≤18 years while 11(12.9%) were aged >35years.Most 
of  the respondents were married and had tertiary level 
of  education. Also, 36(42.4%) of  the respondents were 
primigravida while 28(32.9%) and 21(24.7%) weremulti-
gravida and granmultip respectively as shown in Table I.
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Table I: Socio-demographic and reproductive characteristics of respondents 
   
Variable                                         Subjects n(%)                              Control n(%) 






  2(2.4) 
  
  
2(2.4)   
19-35   72(84.7) 72(84.7) 
>35   11(12.9) 11(12.9) 
p 




  18-42 
  




Marital status   
Single                         2(2.4) - 
Married                         83(97.6)                    85(100.0) 
P value=0.497     
 Level of Education   
No formal education            1(1.1)                      - 
Primary            1(1.1)                   7(8.2) 




           50(58.8)                   51(60.0) 
  





 Occupation     
Civil servant 24(28.2) 33(38.8) 
Trading 34(40.0) 30(35.3) 
House-wife 20(23.6) 22(25.9) 
Student 











































Table  II  shows  the  median  ( 25th-75th percentile val-
ues  of   D-dimer,  tPA,  and  PAI-1  of  subjects as730 
(305.000-1560.000ng/ml),  0.11 (0.065-0.300ng/ml)and 
3.65 (2.970-4.400ng/ml) respectively  which were sig-
nificantly higher than the corresponding values in the 
controls of  520 (240.000-1030.000ng/ml), 0.05 (0.040-
0.090ng/ml), and 2.65 (2.125-3.425ng/ml) respective-
ly,p<0.05 each. However, PT, aPTT and platelet count 
were not significantly different between pre-eclamptics 
and controls.
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Table  II:  Haematological  and  Haemostatic  Parameters   
 among  pre-eclamptics  and controls 
  
 Variables                       Subjects n=85    Controls n=85 
 
 t        /        Mann 




























        
Mean (SD) 35.40 (4.80) 34.40 (1.90) 1.569 0.121 
D-dimer (ng/ml)         






240.00-1030.00    
tPA(Median) 0.11 0.05 *1198.000 0.001 
tPA(25th-
75thpercentile) 
 PAI-1 (ng/ml) 
0.065-0.30 0.040-0.09     
PAI-1(Median) 3.65 2.65 *1609.000 0.001 
PAI-1(25th-
75thpercentile) 
Platelet  count 
(X109/L) 
2.98-4.40 2.13-3.40     






160.00-190.00     
Mean (SD) 35.40 (4.60) 33.00 (3.40) 3.559 0.001 
  
*= Mann Whitney U test 
Discussion
In this study pre-eclampsia was commoner in women be-
tween 19-35 years .This is not in keeping with previous 
reports in which pre-eclampsia   was commoner in wom-
en who were less than 18 years and women older than 35 
years of  age. It is however similar to the findings reported 
by Osunkalu and others.18 The difference in age of  occur-
rence of  pre-eclampsia may be due to the higher level of  
education of  the respondents in this study.
The finding of  the current study in which pre-eclampsia 
was commoner among primiparous women  is supported 
by an earlier  report,19    and may be due  to the absence 
of  effective immunization against placental antigen  by a 
previous pregnancy among primigravidas.20
Prothrombin time (PT) and activated partial thrombo-
plastin time (aPTT) are tests of  extrinsic and intrinsic 
pathway respectively.  Ordinarily,  one would expect that 
the hypercoagulable state in pregnancy would give short-
ened PT and aPTT.In this study, values of  PT and APTT 
were   not  shortened   and   were   similar   in  subjects 
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and  controls.   This  finding   among normotensive  non 
proteinuric controls is similar to the findings of  Jere-
miah,21 but  in contrast to some studies in this environ-
ment,22,23,24  where the values of  PT and aPTT  obtained 
were in support of  an hypercoagulable state.Jeremiah’s 
results on normal pregnant women(subjects)were similar 
to the results of  the normal pregnant women( control) in 
this study ,although he did not study pre-eclamptics and 
there was paucity of  data on the level of  these proteins 
among pre-eclamptics in this environment.The hyper-
coagulability has been attributed to increase in level  of  
coagulation   factors  caused   by  pregnancy   maintain-
ing   hormones   particularly oestrogen  and  progesterone 
which  are  able  to  stimulate  hepatocytes  to produce 
more coagulation  factors.25 However,  nutritional  defi-
ciency  due  to  loss  of   appetite  in  early pregnancy may 
counter balance the increase to give apparently normal 
PT and aPTT values as was found in this study. Also, PT 
and aPTT were not different in both pre-eclamptics and 
normotensive  pregnant women in this study. This is sim-
ilar to what was found by Jahromi et al26 and Mehmet27 
but in contrast to the finding of  Awodu.28 The appar-
ently normal PT and aPTT results among pre-eclamptics 
in these studies may be due to the result of  the balance 
between the hypercoagulability of  normal pregnancy and 
the production of  coagulation inhibitors  which  increas-
es  in  pre-eclampsia.27,29    However,   Awodu  speculated 
that  the prolonged PT in their pre-eclamptics might be 
due to quantitative or qualitative abnormalities of  factors 
in the extrinsic pathway of  coagulation, while the pro-
longed aPTT in another study by Awodu might be caused 
by anti-phospholipid antibodies or lupus anticoagulant.30 
 
It is known that the pathogenesis of  pre-eclampsia is 
associated  with endothelial  cell(EC) dysfunction.  This 
tends  to  increase  the  expression  of   endothelial-  de-
rived  fibrinolytic proteins,  its  inhibitor  and  products 
in  pre-eclamptic  subjects  more  than  in  normotensive 
pregnant women. This is supported by the finding in the 
present study in which plasma levels of  endothelially de-
rived   tPA and PAI-1 were significantly higher in subjects 
than controls.
Similar  to  this,  are  studies  of   several  researchers.31, but 
in contrast  to  the  study  of  Declerck who reported that 
PAI-1 level of  several pre-eclamptic patients were not 
different from  those  obtained  in  normal  pregnancy.34 
The  disparity  of   Declerck  study  may  be attributed to 
the time of  specimen collection.
 
D-dimer is increased in normal pregnancy because of  
compensated state of  low grade intravascular  coagu-
lation;  Moreover,  this  increase  shows  that,  inspite 
of     the  marked impairment  in fibrinolytic potential, 
the fibrinolytic system remains functionally  active. In 
this study, values among pre-eclamptics were significant-
ly higher than the controls indicating an increased intra-
vascular coagulation and activation of  fibrinolysis among 
pre-eclamptics.
This is similar to the findings of  several researchers,21,35,36,37 
Physiological anaemia occurs in pregnancy because of  an 
increase in blood volume that outweighs the increase in 
red cell mass, thus, giving anaemia. In this study, the PCV 
of  the pre-eclamptic subjects were higher than the nor-
motensive non-proteinuric group,  this is similar to the-
study of  Awodu,28  where PCV was also higher among 
pre-eclamptics than the controls. The increased PCV may 
be due to the additional effect  of   haemoconcentration 
in pre-eclampsia.  The haemoconcentration could be as 
a result of  decrease  oncotic pressure  which can create 
a filtration imbalance, further  displacing  intravascular 
fluid.  Also,  endothelial  damage  can  lead  to  pathologic 
capillary leakage of  fluid further causing the haemocon-
centration.
Gestational  thrombocytopaenia  occurs as a result of  
haemodilution,  increased consumption with  reduced 
life  span  and  increased  aggregation  of   platelets by 
increased levels  of  thromboxane A2 at placental circula-
tion.38,39  Also,pre-eclampsia is also one of  the causes of  
thrombocytopaenia  in pregnancy and it is as a result of  
uncontrolled intravascular platelets activation  and  fibrin 
deposition.40 Surprisingly,  Platelet  count  was  not differ-
ent  among subjects and controls in the index study, this 
is  in contrast to a study by Sayin et al.41  The insignificant 
difference in platelet count is due to the relative increase 
in thrombopoetin level in pre-eclampsia.2016
Conclusion
It has been identified that the haemostatic system is ac-
tively involved in pre- eclampsia  and endothelial  derived 
fibrinolytic  proteins are higher in them than in normal 
pregnancy. Thus, measuring these proteins could improve 
obstetrics care.
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However, there were some limitations to this study, this 
includes the fact that non-pregnant women were not in-
vestigated in this study. Therefore, comparism of  mea-
sured parameters between pregnant and non-pregnant 
women could not be done. Thus, the significance of  the 
findings in normal pregnancy could not be substantiated.
Also, the fact that the present study was an hospital based 
has limited its generalizability. Furthermore, most of  the 
subjects presented as emergencies and the baseline blood 
pressure and body weight couldn’t be documented.
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